[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Ito S, Yokomizo S, Imazu T, Sugao H: [Invasive bladder cancer recurrenced 5 years after complete response status by chemotherapy and radiotherapy: a case report]. Hinyokika Kiyo; 2005 Nov;51(11):755-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive bladder cancer recurrenced 5 years after complete response status by chemotherapy and radiotherapy: a case report].
  • A 72-year-old man had undergone trasucethral resection of bladder tumor (TUR-Bt) three times from 1990 to 1991 and he had been lost to follow with no recurrence from 1996, came to our hospital complaining of asymptomatic macrohematuria in May 1999.
  • A bladder tumor existed around the right ureteral orifice with right hydronephrosis.
  • MRI and TUR-Bt revealed that the cancer was transitional cell carcinoma (TCC) > small cell carcinoma, G3, pT3b.
  • Because the patient insisted on bladder preservation, intra arterial chemotherapy with cisplatinum (CDDP) and epirubicin (EPI-adr) followed by radiotherapy with CDDP was performed.
  • The treatment resulted in a clinical complete response (CR), and the bladder was preserved.
  • In January 2004, an invasive bladder cancer recurred at the left lateral wall.
  • This time, neoadjuvant intra-arterial chemotherapy with CDDP and EPI-adr, followed by radical cystectomy was performed.
  • Histologically, the recurrent bladder cancer was TCC, G3, pT3b.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Neoplasm Recurrence, Local / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Humans. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363709.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Yusuke H, Yoshinori H, Kenichi M, Akio H: Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy. Int J Urol; 2006 Oct;13(10):1361-3
Hazardous Substances Data Bank. ISONIAZID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy.
  • We report a rare case of granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin (BCG) instillation therapy in a 58-year-old man, which followed transurethral resection (TUR) for recurrent bladder cancer, when his anterior urethra was slightly narrow and his foreskin was with phimosis.
  • Intravesical BCG instillation therapy was started for prophylaxis of recurrent bladder cancer after TUR.
  • The patient continued chemotherapy with isoniazid for the next 12 months.
  • There was no recurrence of bladder cancer or balanoposthitis for 15 months and to date.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. BCG Vaccine / adverse effects. Balanitis / chemically induced. Granuloma / chemically induced. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Antitubercular Agents / therapeutic use. Biopsy. Follow-Up Studies. Humans. Instillation, Drug. Isoniazid / therapeutic use. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17010022.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antitubercular Agents; 0 / BCG Vaccine; V83O1VOZ8L / Isoniazid
  •  go-up   go-down


3. Iyer G, Milowsky MI, Bajorin DF: Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther; 2010 Dec;10(12):1917-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel strategies for treating relapsed/refractory urothelial carcinoma.
  • Advanced urothelial cancer is associated with a poor prognosis and there has been no substantial progress over the past three decades since the development of platinum-based multiagent chemotherapy.
  • Clinical trials evaluating novel agents and combinations including chemotherapeutic drugs, as well as targeted inhibitors, are desperately needed.
  • With a better understanding of the complex molecular alterations that drive urothelial tumorigenesis, new targets for novel therapeutics are being defined.
  • This article will describe the current state of advanced urothelial cancer treatment and provide a comprehensive discussion of novel agents in development.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Delivery Systems. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Drug Design. Humans. Prognosis. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1937-42 [12085190.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4645-55 [12183421.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52 [12497205.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1546-56 [12684431.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3394-8 [9363871.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2722-7 [9704723.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1189-94 [9815911.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):841-8 [15499627.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3633-41 [15897558.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4902-8 [15930312.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5218-25 [15897885.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1395-401 [16622447.001]
  • [Cites] Oncol Res. 2006;16(1):15-26 [16783964.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9773-8 [16785428.001]
  • [Cites] Nat Rev Genet. 2006 Aug;7(8):606-19 [16847462.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3451-7 [16849761.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):181-5 [16983508.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):522-8 [17229776.001]
  • [Cites] Urology. 2007 Feb;69(2):390-4 [17320695.001]
  • [Cites] Invest New Drugs. 2007 Jun;25(3):265-70 [17146733.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2218-24 [17538166.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):39-51 [17611206.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):759-63 [17594721.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1510-4 [17707060.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Clin Genitourin Cancer. 2007 Dec;5(7):460-3 [18272031.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1625-32 [18347163.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2075-81 [18381947.001]
  • [Cites] Ann Oncol. 2008 May;19(5):946-50 [18272914.001]
  • [Cites] Urology. 2008 Jun;71(6):1220-5 [18538698.001]
  • [Cites] Adv Cancer Res. 2008;100:113-31 [18620094.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):274-81 [18628098.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Int J Clin Oncol. 2008 Aug;13(4):287-97 [18704628.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] Cancer. 2009 Sep 15;115(18):4090-5 [19536901.001]
  • [Cites] Cancer. 2009 Sep 15;115(18):4110-7 [19536904.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6008-17 [19789314.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4454-61 [19687335.001]
  • [Cites] Cancer. 2009 Nov 15;115(22):5143-54 [19658185.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2527-33 [11331332.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1955-9 [11395371.001]
  • [Cites] Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17 [19963098.001]
  • [Cites] Nat Rev Drug Discov. 2010 Jan;9(1):17-8 [20043026.001]
  • [Cites] Cancer Metastasis Rev. 2009 Dec;28(3-4):305-16 [20013032.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1061-8 [20100962.001]
  • [Cites] Oncology (Williston Park). 2010 Jan;24(1):55-62 [20187322.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):1753-8 [20160033.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1373-9 [20142593.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):815-9 [19889613.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1850-5 [20231682.001]
  • [Cites] Cancer. 2010 Apr 15;116(8):1859-71 [20166210.001]
  • [Cites] BJU Int. 2011 Mar;107(5):844-9 [20707797.001]
  • [Cites] Invest New Drugs. 2011 Oct;29(5):1045-9 [20191303.001]
  • [Cites] J Clin Oncol. 2012 Apr 1;30(10):1107-13 [22370319.001]
  • [Cites] Clin Chem. 2003 Oct;49(10):1579-98 [14500583.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8108-12 [14678961.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):220-8 [14665607.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):279-90 [15026548.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):2015-25 [15143095.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4874-84 [15269164.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Urol. 1985 Mar;133(3):403-7 [4038749.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1463-70 [4056840.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):706-9 [2654329.001]
  • [Cites] Mol Carcinog. 1990;3(5):254-7 [1978777.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1974-9 [1525774.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1932-6 [8137220.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2264-70 [7525883.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12 [7563203.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Urol. 1997 Jul;158(1):62-7 [9186324.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] PLoS One. 2008;3(8):e3065 [18725974.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1284-93 [18629841.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5497-510 [18794884.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8022-30 [18829560.001]
  • [Cites] BJU Int. 2008 Nov;102(9 Pt B):1339-44 [19035902.001]
  • [Cites] Oncology (Williston Park). 2008 Nov 30;22(13):1470-9 [19133603.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):663-71 [19114683.001]
  • [Cites] Curr Oncol Rep. 2009 May;11(3):244-9 [19336017.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Apr;9(4):401-12 [19374595.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):993-9 [19150946.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):1074-9 [19168670.001]
  • [Cites] Oncology (Williston Park). 2009 Apr 15;23(4):327-32 [19476261.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3903-5 [19509144.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4213-9 [19509146.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4207-12 [19509177.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2881-90 [19399906.001]
  • [Cites] Urol Oncol. 2009 Jul-Aug;27(4):391-9 [18534874.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Aug;18(8):1183-9 [19604119.001]
  • [Cites] Nat Rev Cancer. 2009 Aug;9(8):550-62 [19629070.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3247-55 [10986057.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4866-73 [11156246.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4874-84 [11156247.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2440-7 [11489824.001]
  • [Cites] J Urol. 2001 Oct;166(4):1275-9 [11547057.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):243-50 [11886001.001]
  • (PMID = 21110758.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207; United States / NCI NIH HHS / CA / T32 CA009207-35
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS327742; NLM/ PMC3705930
  •  go-up   go-down


Advertisement
4. Kaneko T, Fujita K, Homma Y: Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer. Int J Urol; 2006 Mar;13(3):294-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
  • A 76-year-old man received intravesical bacillus Calmette-Guérin (BCG) instillations for recurrent superficial bladder cancer.
  • He had undergone right nephroureterectomy for right renal pelvic cancer 9 months previously.
  • There was no sign of recurrent bladder cancer or ureteral cancer.
  • Most of the side-effects of intravesical BCG therapy are minor, and major adverse reactions are rare.
  • Although BCG intravesical instillation after nephroureterectomy is a common practice, special care should be taken of renal function in patients with unilateral kidney during BCG therapy.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. Anuria / chemically induced. BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Nephrostomy, Percutaneous. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Time Factors. Tomography, X-Ray Computed. Urography

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643629.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


5. Heudel P, El Karak F, Ismaili N, Droz JP, Flechon A: Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience. BMC Urol; 2009;9:5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience.
  • BACKGROUND: Micropapillary bladder cancer is a rare and aggressive variant of urothelial carcinoma.
  • A retrospective review of our experience in management of patients with muscle-invasive or metastatic micropapillary bladder cancer was performed to better define the behavior of this disease.
  • METHODS: We reviewed the records of the 11 patients with micropapillary bladder cancer who were evaluated and treated at Léon Bérard Cancer Center between 1994 and 2007, accounting for 1,2% of all urothelial tumors treated in this institution.
  • Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months.
  • CONCLUSION: Micropapillary bladder cancer is probably an underreported variant of urothelial carcinoma associated with poor prognosis.
  • Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.
  • [MeSH-major] Carcinoma, Papillary / mortality. Carcinoma, Papillary / therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Cancer Care Facilities. Female. France / epidemiology. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Thyroid. 2007 Nov;17(11):1093-6 [18047431.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1590-6 [3171626.001]
  • [Cites] J Urol. 1991 Mar;145(3):459-64; discussion 464-7 [1997689.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 1):302-6; discussion 306-7 [1635123.001]
  • [Cites] Mod Pathol. 1993 Nov;6(6):660-2 [8302807.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] J Urol. 1996 Feb;155(2):495-9; discussion 499-500 [8558644.001]
  • [Cites] J Urol. 1999 Jun;161(6):1798-802 [10332438.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):1-5 [15692943.001]
  • [Cites] Int J Urol. 2005 May;12(5):506-8 [15948755.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):881-5 [16469571.001]
  • [Cites] Int J Urol. 2006 Jul;13(7):1015-8 [16882079.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6 [17504374.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):62-7 [17542024.001]
  • [Cites] Histopathology. 2004 Jul;45(1):55-64 [15228444.001]
  • (PMID = 19534791.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2713271
  •  go-up   go-down


6. Herchenhorn D, Dienstmann R, Peixoto FA, de Campos FS, Santos VO, Moreira DM, Cardoso H, Small IA, Ferreira CG: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol; 2007 Sep-Oct;33(5):630-8; discussion 638
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.
  • OBJECTIVES: Gemcitabine and cisplatin (GC) is an active combination in the treatment of metastatic bladder cancer.
  • We have prospectively analyzed the efficacy and tolerability of GC as neoadjuvant treatment of invasive bladder cancer.
  • MATERIALS AND METHODS: In this single-institution phase II trial, patients with muscle-invasive transitional cell carcinoma received three cycles of gemcitabine 1200 mg/m2 on days 1 and 8 with cisplatin 75 mg/m2 on day 1 prior to surgery.
  • Radiologic response was evaluated by computed tomography and magnetic resonance imaging.
  • All patients were referred to surgery after chemotherapy completion.
  • One patient was excluded due to sarcomatoid carcinoma at definitive pathologic examination.
  • Nine out of 21 patients (43%) relapsed and four (19%) died due to disease progression.
  • Grade III/IV toxicity was infrequent, with no deaths due to chemotherapy.
  • CONCLUSIONS: The combination of GC is effective and well-tolerated when used as neoadjuvant therapy in muscle-invasive bladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int Braz J Urol. 2007 Nov-Dec;33(6):840-1 [18199355.001]
  • (PMID = 17980060.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Clippe C, Clippe S, Yzebe D, Flechon A, Droz JP: [Bladder cancer chemotherapy practice study]. Prog Urol; 2002 Sep;12(4):609-14
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder cancer chemotherapy practice study].
  • [Transliterated title] Etude de pratique de la chimiothérapie dans le cancer de vessie.
  • OBJECTIVE: To study chemotherapy practice in invasive bladder cancer in a cancer centre (Centre Léon Bérard).
  • MATERIAL AND METHODS: This retrospective study concerned all patients treated by chemotherapy between 1994 and 2000, either in the adjuvant setting (38) or for metastatic disease (66).
  • RESULTS: Twenty four of the 38 patients receiving adjuvant chemotherapy were treated with MVAC, 21% developed febrile neutropenia and 60% relapsed.
  • In patients treated for metastatic disease, the objective response rate was 36% and the median survival with advanced disease after chemotherapy was 10 months.
  • The toxicity of chemotherapy was also fairly high (21% of febrile neutropenia).
  • CONCLUSION: Prospective studies help to optimize chemotherapy protocols, but practice studies show the limited results and the high toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Methotrexate / administration & dosage. Neoplasm Invasiveness. Neoplasm Metastasis. Retrospective Studies. Time Factors. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12463119.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


8. Herr HW: Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol; 2008 Jul;54(1):126-32
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
  • OBJECTIVES: To determine the outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
  • METHODS: Between 1995 and 2001, 63 patients were evaluated who declined to undergo a planned cystectomy, because they achieved a complete clinical response to neoadjuvant cisplatin-based chemotherapy.
  • Patient, tumor, and treatment features were assessed prospectively, and correlated in univariate and multivariate analyses with overall survival.
  • The median follow-up was 86 mo and all patients were followed for more than 5 yr.
  • RESULTS: Forty patients (64%) survived, with 54% of them having an intact functioning bladder.
  • The most significant treatment variable predicting better survival was complete resection of the invasive tumor on re-staging transurethral resection before starting chemotherapy.
  • Of 23 patients (36%) who subsequently died of disease, 19 (30%) relapsed with invasive cancer in the bladder.
  • Over 90% of surviving patients had solitary, small, and low-stage invasive tumors completely resected, and 83% survived without relapses in the bladder.
  • CONCLUSIONS: Selected patients with muscle-invasive bladder cancers may survive after transurethral resection and neoadjuvant chemotherapy, and tumor features can identify which patients responding completely to chemotherapy may survive without cystectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Refusal

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Jul;54(1):21-3 [18262722.001]
  • (PMID = 18248875.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Eloubeidi MA, Varadarajulu S, El-Galley R, Bueschen AJ, Eltoum I: EUS-guided FNA for the diagnosis of recurrent bladder cancer through the ileal conduit: a novel approach. Gastrointest Endosc; 2006 Sep;64(3):450-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided FNA for the diagnosis of recurrent bladder cancer through the ileal conduit: a novel approach.
  • BACKGROUND: Diagnosing local recurrence of tumor after cystectomy and ileal conduit construction for urinary bladder cancer remains a diagnostic challenge.
  • Also, distinction of benign stricture from recurrent tumor at the site of ureteral anastomosis in the ileal conduit is difficult.
  • OBJECTIVE: A new method is described for performing EUS-guided FNA through the ileal conduit in patients suspected of having local tumor recurrence after complete cystectomy for bladder cancer.
  • PATIENTS: Three patients who had undergone total cystectomy and ileal conduit construction for bladder cancer underwent EUS-guided FNA through the ileal conduit for evaluation of suspected tumor recurrence at the site of anastomosis of the distal ureter and the ileal conduit.
  • A diagnosis of recurrent transitional cell cancer was made in 2 patients and anastomotic stricture was found in 1 patient.
  • Both patients with tumor recurrence received palliative chemotherapy, and the patient with an anastomotic stricture was managed by placement of a nephrostomy stent.
  • CONCLUSIONS: EUS-guided FNA through the ileal conduit is technically feasible, safe, and establishes diagnosis in patients suspected of tumor recurrence after complete cystectomy for bladder cancer.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography / methods. Neoplasm Recurrence, Local / ultrasonography. Urinary Bladder Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Anastomosis, Surgical. Feasibility Studies. Humans. Male. Middle Aged. Prospective Studies. Ultrasonography, Interventional. Urinary Diversion

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923503.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol; 2007 Oct;52(4):1123-29
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
  • OBJECTIVE: We present a randomised, parallel group, multicentre phase 4 trial comparing short- and long-term chemoprophylaxis with Mitomycin C (MMC) with short-term immunoprophylaxis with Bacillus Calmette-Guérin (BCG) after transurethral resection of the bladder for non-muscle-invasive bladder carcinoma.
  • METHODS: Four hundred ninety-five patients with intermediate- to high-risk non-muscle-invasive bladder cancer (recurrent and/or multifocal pTaG1, TaG2-3, and T1G1-3) were randomised to BCG RIVM 2 x 10(8) CFU weekly for 6 wk, MMC 20 mg weekly for 6 wk, or MMC 20 mg weekly for 6 wk followed by monthly instillations for 3 yr.
  • RESULTS: The 3-yr recurrence-free rates were 65.5% (95%CI, 55.9-73.5%) for short-term BCG, and 68.6% (59.9-75.7%) for short-term MMC, whereas recurrence-free rates were significantly increased to 86.1% (77.9-91.4%) in patients with MMC long-term therapy (log-rank test, p=0.001).
  • CONCLUSIONS: Long-term MMC significantly reduced the risk of tumour recurrence without enhanced toxicity compared with both short-term BCG and MMC in patients with intermediate- and high-risk non-muscle-invasive bladder carcinoma.
  • Our data provide a rationale for maintenance intravesical chemotherapy in this population.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Mitomycin / administration & dosage. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Regression Analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Oct;52(4):1129-30 [17383082.001]
  • [CommentIn] Eur Urol. 2007 Oct;52(4):951-3; discussion 953-4 [17374437.001]
  • (PMID = 17383080.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine; 50SG953SK6 / Mitomycin
  •  go-up   go-down


11. Deng X, Wu Y, Jiang Y, Cong P, Li S: [Preoperative superselective intra-internal iliac arterial chemotherapy for invasive bladder cancer and curative analysis]. Zhonghua Wai Ke Za Zhi; 2000 Apr;38(4):278-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative superselective intra-internal iliac arterial chemotherapy for invasive bladder cancer and curative analysis].
  • OBJECTIVE: To study clinical effects of preoperative intra-internal iliac-arterial chemotherapy for invasive bladder cancer.
  • METHODS: 14 cases of invasive bladder cancer underwent superselective intra-internal iliac-arterial chemotherapy before conservative cystectomy.
  • RESULTS: After 2-3 week therapy, reduction of cancer volume (20%-50%), clotted by thrombus in the blood vessels of the cancer or circumferential tissue, and decreased bleeding were found.
  • Pathomorphological features included large patchy necrosis, degeneration, and inflammatory changes of carcinoma tissue.
  • One T3 N1 M0) of the cases (0.7%) relapsed into T1N0M0 and the others did not.
  • CONCLUSIONS: The intra-internal iliac-arterial method, simple, safe, coordinates in pre-operation for invasive bladder cancer, and increases the operative opportunity for preservation of functional bladder.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Chemoembolization, Therapeutic. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy / methods. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Preoperative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12828164.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I: Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol; 2009 Oct;182(4):1313-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
  • PURPOSE: Despite an initial adequate response many patients with nonmuscle invasive urothelial cell carcinoma of the bladder eventually have recurrence after intravesical bacillus Calmette-Guerin treatments.
  • We evaluated the efficacy of combined bladder wall hyperthermia and intravesical mitomycin C instillation (thermo-chemotherapy) in cases of recurrence after bacillus Calmette-Guerin.
  • MATERIALS AND METHODS: A total of 111 patients with recurrent papillary nonmuscle invasive urothelial cell carcinoma of the bladder after previous bacillus Calmette-Guerin treatment underwent complete bladder tumor resection and were referred for prophylactic adjuvant treatment with thermo-chemotherapy.
  • Treatment was received on an outpatient basis weekly for 6 weeks, followed by 6 maintenance sessions at 4 to 6-week intervals.
  • Each treatment included 2, 30-minute cycles of 20 mg mitomycin C and bladder wall hyperthermia to 42C +/- 2C.
  • Cystoscopy and urine cytology were performed after the completion of induction treatment and every 3 months thereafter.
  • No maintenance treatment was associated with decreased efficacy, that is the recurrence rate was 61% at 2 years vs 39% in those with maintenance treatments (p = 0.01).
  • CONCLUSIONS: Thermo-chemotherapy may be effective for papillary nonmuscle invasive urothelial cell carcinoma of the bladder that recurs after BCG treatment without increasing the risk of tumor progression.
  • Maintenance therapy is important and improves the outcome.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Hyperthermia, Induced. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Administration, Intravesical. Adult. Aged. Aged, 80 and over. BCG Vaccine / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 Oct;182(4):1317; discussion 1317 [19683279.001]
  • (PMID = 19683278.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / BCG Vaccine; 50SG953SK6 / Mitomycin
  •  go-up   go-down


13. Campbell C, Soulen MC, Horii SC, Seigelman ES, Rubesin SE, Vaughn DJ: Transrectal radiofrequency ablation for pelvic recurrence of bladder cancer: case report and review of complications. J Vasc Interv Radiol; 2005 Jul;16(7):1027-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transrectal radiofrequency ablation for pelvic recurrence of bladder cancer: case report and review of complications.
  • Treatment options are frequently limited by previous radiation and inefficacy of systemic chemotherapy.
  • In the present case, transrectal RF ablation of recurrent bladder cancer was performed for palliation of intractable pain.
  • [MeSH-major] Catheter Ablation / methods. Pelvic Neoplasms / surgery. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002513.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Halling KC, Kipp BR: Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol; 2008 Sep;15(5):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer detection using FISH (UroVysion assay).
  • UroVysion is a fluorescence in situ hybridization assay that was developed for the detection of bladder cancer in urine specimens.
  • The UroVysion assay works by detecting urinary cells that have chromosomal abnormalities consistent with a diagnosis of bladder cancer.
  • Studies have shown that UroVysion is more sensitive than urine cytology for the detection of all stages and grades of bladder cancer.
  • UroVysion is Food and Drug Administration-approved for the detection of recurrent bladder cancer in voided urine specimens from patients with a history of bladder cancer and for the detection of bladder cancer in voided urine specimens from patients with gross or microscopic hematuria, but no previous history of bladder cancer.
  • Recent studies also suggest that UroVysion may be useful for assessing superficial bladder cancer patients' response to bacillus Calmette-Guerin therapy and in detecting upper tract urothelial carcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / urine. In Situ Hybridization, Fluorescence. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] BCG Vaccine / therapeutic use. BK Virus. Chromosome Aberrations. Device Approval. Hematuria / diagnosis. Humans. Polyomavirus Infections / diagnosis. Sensitivity and Specificity. Urine / cytology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724101.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 48
  •  go-up   go-down


15. Chiang PH, Chiang CP: Intravesical mitoxantrone in superficial bladder cancer. Kaohsiung J Med Sci; 2000 Feb;16(2):91-4
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical mitoxantrone in superficial bladder cancer.
  • Twenty-five patients with Ta-T1 transitional cell carcinoma of the bladder were treated by transurethral resection (TUR) followed by intravesical chemoprophylaxis with mitoxantrone (10 mg diluted in 50 ml normal saline) administered weekly for 6 weeks.
  • After a mean follow-up of 12 months, 76% of patients in the whole group, 69% in the newly diagnosed patients and 89% in the group of previously relapsed patients remained relapse free.
  • Therapy was well tolerated in most patients, with only two patients reporting grade 3 local toxicity.
  • We conclude that mitoxantrone is an effective and safe agent for intravesical chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Mitoxantrone / administration & dosage. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10816992.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


16. Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, Fragapane G: [Neuroendocrine small-cell bladder cancer: our experience]. Urologia; 2010 Oct-Dec;77 Suppl 17:64-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine small-cell bladder cancer: our experience].
  • [Transliterated title] Carcinoma neuroendocrino a piccole cellule della vescica; nostra esperienza.
  • INTRODUCTION: Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.35-0.70% of all bladder tumors.
  • The small-cell carcinoma represents the most frequent histologic variant described.
  • Small-cell carcinoma is an epithelial tumor associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma.
  • At the time of presentation 59% of patients have clinical stage >T2 and 56% show metastatic disease.
  • PATIENTS AND METHODS: We report three cases of pure neuroendocrine small-cell bladder cancer.
  • Two patients were treated by radical cystectomy, bilateral pelvic limph node resections and urinary derivation.
  • Platinum-based adjuvant chemotherapy was proposed but only two patients received the treatment.
  • RESULTS: In 2 patients residual or relapsed cancer reappered within 2 months after surgery.
  • CONCLUSIONS: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain.
  • Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach will be the treatment of choice.
  • The association of chemotherapy and radiotherapy should also be considered.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hematuria / etiology. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Leukemia, Lymphocytic, Chronic, B-Cell. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasms, Second Primary. Peritoneal Neoplasms / secondary. Prostatic Neoplasms. Stomach Neoplasms. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308678.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Linn JF, Black P, Derksen K, Rübben H, Thüroff JW: Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results. Eur Urol; 2000;37 Suppl 3:34-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results.
  • In 1974, Olson studied the immune competence of bladder cancer patients by intradermal application of KLH.
  • He later observed a significant reduction of recurrent disease in this patient group compared to another not immunized with KLH.
  • This prompted a variety of experimental and clinical studies using KLH as an immunotherapy for recurrent bladder cancer.
  • METHODS: Three different bladder cancer models have been used for experimental studies: intravesical transplantation of tumour cells in syngeneic mouse bladders; subcutaneous transplantation of tumour cells in syngeneic mice; direct chemical induction of bladder tumours by feeding rats with the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine.
  • However, most of the experiments demonstrated a significant effect on tumour appearance and extension after treatment with KLH.
  • Intralesional or systemic application of KLH seemed to be superior to intravesical treatment.
  • CONCLUSION: Based on all the experimental studies, KLH has to be judged as an effective and safe immunotherapeutic drug for the treatment of experimental bladder cancer.
  • Prospective randomised clinical trials should evaluate the role of KLH as an immunotherapeutic alternative in the prophylaxis of recurrent bladder cancer and should determine whether the efficacy of KLH in man may be improved by systemic application.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Hemocyanin / therapeutic use. Neoplasms, Experimental / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10828685.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  • [Number-of-references] 35
  •  go-up   go-down


18. Neuzillet Y, Cabaniols L, Karam G, Salomon L, Barrou B, Petit J, Feuillu B, Lechevallier E: [Study of urothelial bladder tumours in renal transplant recipients]. Prog Urol; 2006 Jun;16(3):343-6
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of urothelial bladder tumours in renal transplant recipients].
  • [Transliterated title] Etude des tumeurs urothéliales de vessie chez les transplantés rénaux.
  • OBJECTIVE: To study the prevalence, treatment and outcome of urothelial bladder tumours (UBT) in renal transplant recipients.
  • 7 patients underwent cystectomy, with a palliative objective in 42% of cases, associated with radiotherapy-chemotherapy (2/3) or chemotherapy alone (1/3).
  • Immunosuppressive therapy was decreased in 50% of cases.
  • Six patients (25%) died from bladder cancer, 25% relapsed with a tumour progression rate of 50%.
  • Increased surveillance and aggressive treatment therefore appear to be justified.
  • [MeSH-major] Kidney Transplantation. Postoperative Complications. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821348.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


19. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs; 2007 Jun;25(3):265-70
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
  • PURPOSE: The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma.
  • METHODS: Patients with advanced urothelial carcinoma that had relapsed after receiving perioperative chemotherapy, or progressed on first-line chemotherapy for metastatic disease, were eligible for enrollment.
  • Treatment was generally well tolerated, however, 2/13 patients developed febrile neutropenia.
  • CONCLUSIONS: Pemetrexed as second-line therapy in advanced urothelial carcinoma is associated with modest activity.
  • The role of this novel antifolate in chemotherapy-naïve patients warrants further investigation.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Pelvic Neoplasms / drug therapy. Salvage Therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy. Urothelium / pathology
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Humans. Infusions, Intravenous. Pemetrexed. Treatment Outcome. Vitamin B 12 / administration & dosage. Vitamin B 12 / therapeutic use. Vitamin B Complex / administration & dosage. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):69-75 [12571815.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1395-401 [16622447.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):589-93 [9053481.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):937-40 [11844814.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):506-13 [16773629.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1627-32 [16138364.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3451-7 [16849761.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35 [16322992.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):552-62 [16391300.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 17146733.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 12001-76-2 / Vitamin B Complex; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


20. Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G: [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ]. Urologia; 2010 Oct-Dec;77 Suppl 17:72-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
  • [Transliterated title] Recidiva uretrale di Ca infiltrante dopo trattamento con BCG per Ca in situ vescicale.
  • CIS is a flat, high-grade, non-invasive microscopic urothelial carcinoma.
  • It is considered a precursor of invasive bladder cancer.
  • CIS is classified as primary, secondary or concurrent, when occurred as isolated CIS without cuncurrent papillary tumors, or detected during the follow-up of patients with a previous papillary tumor, or finally in the presence of bladder neoplasm.
  • BCG is widely established as the treatment of choice for CIS with a success rate of approximately 70%.
  • BCG reduces the risk of progression of CIS into invasive carcinoma in 30 to 50% of cases.
  • Direct and prolonged contact between the urothelium and BCG is a prerequisite for successful therapy.
  • CIS may be present only in the epithelial lining of the prostatic urethra or in the ducts, or in the worst case it may be found in the prostatic tissue stroma.
  • 83 patients, enrolled from 1/1996 to 12/2005 at our urological department with CIS: primary (focal and multifocal) in 25, secondary in 7 and cuncurrent in 51 (associated with T1bG3 cancer in 37 cases), and urethral CIS in 5 and conservatively treated by TUR and intravescical instillations of BCG, 4 developed afterwords only invasive cancer of the urethra in the absence of bladder involvement.
  • In 2 cases cancer arised from the prostatic fossa after TURP, in 1 from membranous urethra and in the last from prostatic ducts.
  • Among the 4 patients, 3 were treated by cystoprostatourethrectomy and Platinum-based chemotherapy, 1 refused surgical treatment.
  • In the last patient cancer relapsed at 36-month's follow-up.
  • We conclude that prostatic/urethral involvement during follow-up after successful intravesical treatment with BCG in CIS represents a high risk of developing invasive and incontrolled cancer.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / secondary. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy / methods. Disease Progression. Female. Follow-Up Studies. Humans. Immunotherapy. Male. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Prostatectomy / methods. Prostatic Neoplasms / secondary. Risk. Treatment Outcome. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308679.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Organoplatinum Compounds
  •  go-up   go-down


21. Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D, James ND: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer; 2004 Aug 31;91(5):844-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
  • In all, 32 patients with locally advanced, relapsed, or metastatic disease received: dose level 1, G/C 1000/35; level 2, 1100/35; level 3, 1200/35; level 4, 1200/45 mg m(-2) (G and C given on days 1 and 8 every 3 wks).
  • Only seven cycles were deferred due to haematological toxicity; four for renal toxicity (chemotherapy instituted posthydration).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Maximum Tolerated Dose. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Kidney / drug effects. Kidney Function Tests. Lymphatic Metastasis / pathology. Male. Middle Aged. Outpatients. Treatment Outcome. Viscera / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Curr Opin Urol. 2002 Sep;12(5):441-8 [12172434.001]
  • [Cites] Lancet Oncol. 2003 Aug;4(8):489-97 [12901963.001]
  • [Cites] J Urol. 1985 Mar;133(3):403-7 [4038749.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1463-70 [4056840.001]
  • [Cites] J Urol. 1989 Aug;142(2 Pt 1):289-92 [2746745.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] Urology. 1989 Dec;34(6):353-6 [2595880.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] J Urol. 1990 Sep;144(3):662-5 [2388322.001]
  • [Cites] Eur J Cancer. 1991;27(12):1690-4 [1782084.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • (PMID = 15292922.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2409873
  •  go-up   go-down


22. Gunelli R, Bercovich E, Nanni O, Ballardini M, Frassineti GL, Giovannini N, Fiori M, Pasquini E, Ulivi P, Pappagallo GL, Silvestrini R, Zoli W: Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer; 2007 Dec 3;97(11):1499-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
  • Intravesical gemcitabine (Gem) has shown promising activity against transitional cell carcinomas (TCC) of the bladder, with moderate urinary toxicity and low systemic absorption.
  • The present phase II study evaluated the activity of biweekly intravesical treatment with Gem using a scheme directly derived from in vitro preclinical studies.
  • Patients with Bacille Calmette-Guérin (BCG) -refractory Ta G3, T1 G1-3 TCC underwent transurethral bladder resection and then intravesical instillation with 2000 mg Gem diluted in 50 ml saline solution on days 1 and 3 for 6 consecutive weeks.
  • Thirty-eight (95%) of the 40 patients showed persistent negative post-treatment cystoscopy and cytology 6 months after Gem treatment, while the remaining 2 patients relapsed at 5 and 6 months.
  • Urinary and systemic toxicity was very low, with no alterations in biochemical profiles.
  • Our results highlight the importance of preclinical studies using in vitro systems that adequately reproduce the conditions of intravesical clinical treatment to define the best therapeutic schedule.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. BCG Vaccine / therapeutic use. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. Survival Analysis. Technology Transfer

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2000;37 Suppl 1:16-20 [10575267.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2729-34 [16782913.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3193-8 [12149290.001]
  • [Cites] J Urol. 2002 Nov;168(5):1964-70 [12394686.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):697-703 [12586808.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1500-7 [14977854.001]
  • [Cites] BJU Int. 2004 Mar;93(4):491-4 [15008715.001]
  • [Cites] Eur Urol. 2004 Sep;46(3):339-43 [15306105.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):117-21 [3334986.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 [2359136.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):385-90 [9523734.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] J Urol. 1999 Apr;161(4):1124-7 [10081852.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2629-37 [10499642.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1185-91 [15718315.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2381-4 [16080464.001]
  • [Cites] Hinyokika Kiyo. 2005 Aug;51(8):533-8 [16164269.001]
  • [Cites] Urology. 2005 Oct;66(4):726-31 [16230125.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jan;37(1):69-82 [11164721.001]
  • (PMID = 17987035.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / BCG Vaccine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2360270
  •  go-up   go-down


23. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol; 2006 Jul 20;24(21):3451-7
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
  • PURPOSE: To assess the antitumor activity and toxicity of pemetrexed as second-line chemotherapy in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium.
  • PATIENTS AND METHODS: Eligible patients had a performance status of 0 or 1, adequate organ function, previous treatment with one prior chemotherapy regimen for locally advanced or metastatic TCC of the urothelium or relapsed within 1 year of adjuvant or neoadjuvant treatment.
  • The median time to progressive disease was 2.9 months (95% CI, 1.7 months to 4.6 months) and median overall survival was 9.6 months (95% CI, 5.1 months to 14.6 months).
  • CONCLUSION: Single-agent pemetrexed is safe and active as second-line treatment of patients with advanced TCC of the urothelium.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy. Urothelium
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Pemetrexed. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


24. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • BACKGROUND: Palliative radiation therapy (RT) is an established tool in the management of symptoms caused by malignancies.
  • RT is effective at palliating both locally advanced and metastatic cancer, including related symptoms of pain, bleeding, or obstruction.
  • Most data on palliative RT is in regard to its use in the treatment of painful bone metastases.
  • There are also data that support RT palliation for locally advanced or recurrent rectal, prostate, and gynecological cancers.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • After undergoing 4 cycles of adjuvant chemotherapy, the patient did well for 5 months with no evidence of symptomatic, clinical, or radiographic recurrence of disease.
  • The patient was treated with another course of chemotherapy and pain was managed with relatively low doses of opioid medication (25mcg transdermal fentanyl patch, and oxycodone 5mg bid).
  • Ultimately a pain medication regimen of 200mcg transdermal fentanyl patch q2 days, oxycontin 20mg bid, oxycodone 5 - 10mg q 4 hours, ibuprofen 400mg q 8 hours, and gabapentin 600mg TID was not effective in controlling pain.
  • She was able to decrease pain medications, increase overall activity, and gain significant improvement in sleep quality and appetite even early on in the course of her radiation therapy.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • Palliative RT is an important component in the multimodality approach to cancer pain management and optimization of quality of life.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pain / radiotherapy. Palliative Care / methods. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387350.001).
  • [ISSN] 1533-3159
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dumez H, Gallardo E, Culine S, Galceran JC, Schöffski P, Droz JP, Extremera S, Szyldergemajn S, Fléchon A: Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar Drugs; 2009;7(3):451-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium.
  • The objective of this exploratory, open-label, single-arm, phase II clinical trial was to evaluate plitidepsin (5 mg/m(2)) administered as a 3-hour continuous intravenous infusion every two weeks to patients with locally advanced/metastatic transitional cell carcinoma of the urothelium who relapsed/progressed after first-line chemotherapy.
  • Treatment cycles were repeated for up to 12 cycles or until disease progression, unacceptable toxicity, patient refusal or treatment delay for >2 weeks.
  • Secondary endpoints were the rate of SD lasting > or = 6 months and time-to-event variables.
  • Twenty-one patients received 57 treatment cycles.
  • Treatment was feasible and generally well tolerated in this patient population; however the lack of antitumor activity precludes further studies of plitidepsin in this setting.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Depsipeptides / pharmacology. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2971-94 [10561376.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):517-23 [19117344.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3558-85 [11032599.001]
  • [Cites] Oncology (Williston Park). 2001 Jun;15(6):763-71, 775; discussion 775-6, 779-80 [11430208.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):937-40 [11844814.001]
  • [Cites] Onkologie. 2002 Feb;25(1):47-52 [11893883.001]
  • [Cites] Curr Treat Options Oncol. 2001 Oct;2(5):431-6 [12057106.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7533-44 [12386816.001]
  • [Cites] Leukemia. 2003 Jan;17(1):52-9 [12529660.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):321-9 [15057135.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2418-24 [15173857.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4673-80 [15122339.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):589-93 [9053481.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):739-44 [9743292.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Urol. 2005 Jul;174(1):14-20 [15947569.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1667-74 [16014640.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7871-80 [16172454.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(1):7-14 [16001179.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3451-7 [16849761.001]
  • [Cites] Ann Oncol. 2006 Sep;17(9):1371-8 [16966366.001]
  • [Cites] Cell Death Differ. 2006 Nov;13(11):1968-81 [16543941.001]
  • [Cites] Jpn J Clin Oncol. 2007 Mar;37(3):201-6 [17452426.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):759-63 [17594721.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3105-12 [18483378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 19841725.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Depsipeptides; Y76ID234HW / aplidine
  • [Other-IDs] NLM/ PMC2763111
  • [Keywords] NOTNLM ; TCC / plitidepsin / second-line / transitional cell carcinoma / urothelium
  •  go-up   go-down


26. Quach H, Januszewicz H, Westerman D: Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica; 2005 Nov;90 Suppl:ECR26
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
  • Rituximab treatment in relapsed or refractory HCL results in a CR of 13% to 53%, but its use in HCL-v has not been reported in the literature to our knowledge.
  • We describe a patient with HCL-v, whose course was previously complicated by pure red cell aplasia who achieved CR after treatment with rituximab.
  • We also briefly review outcomes of treatments used in HCL-v reported in the current literature.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Red-Cell Aplasia, Pure / etiology
  • [MeSH-minor] 2-Chloroadenosine / administration & dosage. 2-Chloroadenosine / analogs & derivatives. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Transfusion. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Deoxyadenosines / administration & dosage. Disease Progression. Drug Resistance, Neoplasm. Fatal Outcome. Humans. Interferon-alpha / administration & dosage. Male. Prednisolone / administration & dosage. Recurrence. Remission Induction. Rituximab. Splenectomy. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266917.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Deoxyadenosines; 0 / Interferon-alpha; 115044-75-2 / 2-chloro-3'-deoxyadenosine; 146-77-0 / 2-Chloroadenosine; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


27. Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group: Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol; 2009 Aug;56(2):260-5
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
  • BACKGROUND: The long-term prospective data on bacillus Calmette-Guérin (BCG) and mitomycin C (MMC) instillation therapy are limited.
  • OBJECTIVE: To compare the long-term benefit of BCG and MMC maintenance therapy in patients with recurrent bladder carcinoma.
  • DESIGN, SETTING, AND PARTICIPANTS: Eighty-nine patients with frequently recurrent TaT1 disease without carcinoma in situ (CIS) were eligible.
  • Because of alkalinising the urine and adjusting the dose to bladder capacity, the average concentration of MMC was low: 30-40 mg in 150-200 ml of phosphate buffer.
  • Overall median follow-up time was 8.5 yr, whereas the median follow-up time of the patients who were still alive was 19.4 yr.
  • MEASUREMENTS: Primary end points were time to first recurrence and overall mortality.
  • There was a weak trend for fewer progressions (p=0.1) and cancer-specific deaths (p=0.2) in the cumulative incidence analysis, as 4 patients versus 10 patients progressed and 4 patients versus 9 patients died from the disease in the BCG group versus the MMC group, respectively.
  • CONCLUSIONS: An intensive intravesical BCG immunotherapy results in a sustained and significant long-term reduction in recurrence in frequently recurrent bladder carcinoma.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. BCG Vaccine / therapeutic use. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Randomized Controlled Trials as Topic. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Aug;56(2):266-8; discussion 268-9 [19427110.001]
  • (PMID = 19395154.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / BCG Vaccine; 50SG953SK6 / Mitomycin
  •  go-up   go-down


28. Tsai MK, Chueh SC, Hu RH, Lee PH: Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection. J Formos Med Assoc; 2003 Feb;102(2):91-6
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Sirolimus is a novel immunosuppressive drug with much less nephrotoxicity than cyclosporine.
  • The efficacy and toxicity of the combination of sirolimus and low-dose cyclosporine therapy were compared with data from records of a previous cyclosporine-based regimen used in patients with renal allograft transplantation.
  • The efficacy and adverse effects of the combined therapy were compared with those recorded in medical records of 24 renal transplant recipients who had received a cyclosporine-based regimen (10 mg/kg/day).
  • One patient in the study group died of complications sustained during a radical operation for recurrent bladder carcinoma during the sixth post-transplant month.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12709737.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; W36ZG6FT64 / Sirolimus; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


29. Leach TD, Sadek SA, Mason JC: An unusual abdominal mass in a renal transplant recipient. Transpl Infect Dis; 2002 Dec;4(4):218-22
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 72-year-old-man with recurrent bladder carcinoma, abdominal aortic aneurysm repair, and end-stage renal failure due to renovascular disease.
  • He received a cadaveric renal allograft into his left iliac fossa, was given cyclosporin A, azathioprine, and prednisolone triple therapy immunosuppression, and had no rejection episodes.
  • This time he had right iliac fossa pain of three weeks' duration.
  • Ultrasonography and computed tomography detailed an infiltrating mass associated with the sigmoid colon, which colonoscopy failed to visualise.
  • At laparotomy a 6-cm tumor was removed, with adherent sigmoid colon and bladder dome.
  • [MeSH-minor] Abdominal Abscess. Actinomyces / growth & development. Aged. Antifungal Agents / therapeutic use. Cefaclor / pharmacology. Cefaclor / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Opportunistic Infections / diagnosis. Opportunistic Infections / drug therapy. Opportunistic Infections / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12535266.001).
  • [ISSN] 1398-2273
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Immunosuppressive Agents; 69K7K19H4L / Cefaclor
  •  go-up   go-down






Advertisement